关注
Miriam Longo
Miriam Longo
General and Internal Medicine
在 unimi.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Alcohol or gut microbiota: who is the guilty?
M Meroni, M Longo, P Dongiovanni
International journal of molecular sciences 20 (18), 4568, 2019
1192019
miRNA signature in NAFLD: a turning point for a non-invasive diagnosis
P Dongiovanni, M Meroni, M Longo, S Fargion, AL Fracanzani
International journal of molecular sciences 19 (12), 3966, 2018
1032018
The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies
M Meroni, M Longo, P Dongiovanni
Nutrients 11 (11), 2642, 2019
882019
Genetic and epigenetic modifiers of alcoholic liver disease
M Meroni, M Longo, R Rametta, P Dongiovanni
International journal of molecular sciences 19 (12), 3857, 2018
782018
Nutrition and genetics in NAFLD: the perfect binomium
M Meroni, M Longo, A Rustichelli, P Dongiovanni
International Journal of Molecular Sciences 21 (8), 2986, 2020
652020
Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
M Meroni, P Dongiovanni, M Longo, F Carli, G Baselli, R Rametta, ...
EBioMedicine 52, 2020
612020
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?
M Longo, M Meroni, E Paolini, C Macchi, P Dongiovanni
Metabolism 117, 154708, 2021
482021
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients
P Dongiovanni, M Meroni, G Baselli, RM Mancina, M Ruscica, M Longo, ...
Journal of lipid research 60 (6), 1144-1153, 2019
462019
MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
M Meroni, M Longo, AL Fracanzani, P Dongiovanni
EBioMedicine 57, 2020
302020
MAFLD in COVID-19 patients: an insidious enemy
P Dongiovanni, M Meroni, M Longo, AL Fracanzani
Expert Review of Gastroenterology & Hepatology 14 (10), 867-872, 2020
292020
TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models
M Longo, M Meroni, E Paolini, V Erconi, F Carli, F Fortunato, D Ronchi, ...
Cellular and Molecular Gastroenterology and Hepatology 13 (3), 759-788, 2022
282022
mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance
M Meroni, M Longo, V Erconi, L Valenti, S Gatti, AL Fracanzani, ...
Nutrients 11 (11), 2597, 2019
272019
Remodeling of mitochondrial plasticity: the key switch from NAFLD/NASH to HCC
M Longo, E Paolini, M Meroni, P Dongiovanni
International Journal of Molecular Sciences 22 (8), 4173, 2021
262021
Genetics is of the essence to face NAFLD
M Meroni, M Longo, G Tria, P Dongiovanni
Biomedicines 9 (10), 1359, 2021
252021
Low lipoprotein (a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease
M Meroni, M Longo, R Lombardi, E Paolini, C Macchi, A Corsini, ...
Hepatology Communications 6 (3), 535-549, 2022
122022
The rs599839 A> G variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients
M Meroni, M Longo, E Paolini, A Alisi, L Miele, ER De Caro, G Pisano, ...
Cancers 13 (8), 1783, 2021
122021
Genetics, immunity and nutrition boost the switching from NASH to HCC
P Dongiovanni, M Meroni, M Longo, S Fargion, AL Fracanzani
Biomedicines 9 (11), 1524, 2021
102021
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD
P Dongiovanni, M Meroni, S Petta, M Longo, A Alisi, G Soardo, L Valenti, ...
Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2020
92020
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
N Panera, M Meroni, M Longo, A Crudele, L Valenti, E Bellacchio, L Miele, ...
EBioMedicine 65, 2021
82021
Genetic and metabolic factors: The perfect combination to treat metabolic associated fatty liver disease
M Meroni, M Longo, P Dongiovanni
EXPLORATION OF MEDICINE. 1 (4), 218-243, 2020
72020
系统目前无法执行此操作,请稍后再试。
文章 1–20